Technology Transfer and Industry News

Wednesday, 27 June 2018

ICN2 shares scientific knowledge and applications at Graphene 2018

Graphene 2018 is being held in Dresden (Germany) from 26 to 29 June 2018. ICN2 is there once again with organisational, institutional and scientific efforts to share the latest advances in graphene research. Drop by the ICN2 booth to learn about brain implants to restore speech or nanoporous graphene, among other breakthroughs.

Tuesday, 26 June 2018

Ahead Therapeutics will participate in the Boston Immersion Program

The spin-off receives the UAB Research Park and Catalunya Emprèn scholarship and will have the opportunity to attend the 2018 edition of the Boston Entrepreneurship Program at Richi Entrepreneurs, from October 15 to November 2, 2018. The objective of this program is to identify and train entrepreneurial talent for social innovation projects.

Monday, 26 March 2018

Paperdrop is among the spin offs selected to be accelerated by EMPENTA

EMPENTA is the acceleration and support program for technology-based companies promoted by ACCIÓ (Catalan Government) and led by ESADE and ESADECREAPOLIS. In its seventh edition over 130 projects have been registered, doubling the numbers of the previous edition.

Thursday, 12 April 2018

The spinoff adventure: sharing knowledge and experiences

Last week ICN2 Business Development Officer Nadia Pons gave a talk outlining the institute’s spinoff creation policy and encouraged in-house researchers to get involved in entrepreneurial projects. The session was then opened to the whole of the university campus for a presentation by Barcelona Activa to promote its 2018 pre-accelerator programme for business creation.

Tuesday, 23 January 2018

New spin-off Ahead Therapeutics SL to develop novel therapies for autoimmune diseases

Ahead Therapeutics SL is the result of a joint research project with a strong nano component between the Germans Trias i Pujol Research Institute (IGTP), the ICN2 and ICREA. It was created to advance the development of therapies for autoimmune diseases and pursue their application in a clinical setting. Just a few months in, the new company has already attracted 1.1 million euros in private investment.